Abstract
At the present time, there is no widely agreed definition of postprandial lipaemia (PPL). This lack of a shared definition limits the identification and treatment of patients with exaggerated PPL as well as the evaluation of potential therapeutic agents. PPL is a complex syndrome characterized by non-fasting hypertriglyceridaemia that is associated with an increased risk of vascular events. This review considers the definition of PPL and the methodology for assessing this process.
Keywords: Definition, non-fasting hypertriglyceridaemia, postprandial lipaemia, triglycerides, hypertension, obesity, diabetes mellitus, low density lipoprotein, hypercholesterolaemia, chylomicrons
Current Vascular Pharmacology
Title: Definition of Postprandial Lipaemia
Volume: 9 Issue: 3
Author(s): Genovefa D. Kolovou, Dimitri P. Mikhailidis, Borge G. Nordestgaard, Helen Bilianou and George Panotopoulos
Affiliation:
Keywords: Definition, non-fasting hypertriglyceridaemia, postprandial lipaemia, triglycerides, hypertension, obesity, diabetes mellitus, low density lipoprotein, hypercholesterolaemia, chylomicrons
Abstract: At the present time, there is no widely agreed definition of postprandial lipaemia (PPL). This lack of a shared definition limits the identification and treatment of patients with exaggerated PPL as well as the evaluation of potential therapeutic agents. PPL is a complex syndrome characterized by non-fasting hypertriglyceridaemia that is associated with an increased risk of vascular events. This review considers the definition of PPL and the methodology for assessing this process.
Export Options
About this article
Cite this article as:
D. Kolovou Genovefa, P. Mikhailidis Dimitri, G. Nordestgaard Borge, Bilianou Helen and Panotopoulos George, Definition of Postprandial Lipaemia, Current Vascular Pharmacology 2011; 9 (3) . https://dx.doi.org/10.2174/157016111795495611
DOI https://dx.doi.org/10.2174/157016111795495611 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Identification of Genes for a Complex Trait: Examples from Hypertension
Current Pharmaceutical Biotechnology Vascular Effects of Estrogenic Menopausal Hormone Therapy
Reviews on Recent Clinical Trials Left Ventricular Non-compaction: From Recognition to Treatment
Current Pharmaceutical Design Social Determinants, Race, and Brain Health Outcomes: Findings from the Chicago Health and Aging Project
Current Alzheimer Research Trans-Resveratrol: A Magical Elixir of Eternal Youth?
Current Medicinal Chemistry Natural Naphthoquinones with Great Importance in Medicinal Chemistry
Current Organic Synthesis Trypanosomatid Parasites Causing Neglected Diseases
Current Medicinal Chemistry Novel Anti-arrhythmic Medications in the Treatment of Atrial Fibrillation
Current Cardiology Reviews Waist-to-Hip Ratio (WHR) is Conversely Correlated to LAMP-2 Gene Expression Level: A Predictor for Lysosomal Lipid Entrance System
Current Nutrition & Food Science Scorpion Toxin Polyptides as Therapeutic Agents: An Overview
Protein & Peptide Letters Stem Cell Therapy for Ischaemic Stroke: Translation from Preclinical Studies to Clinical Treatment
CNS & Neurological Disorders - Drug Targets The Role of the Methoxyphenol Apocynin, a Vascular NADPH Oxidase Inhibitor, as a Chemopreventative Agent in the Potential Treatment of Cardiovascular Diseases
Current Vascular Pharmacology MicroRNAs as Early Biomarkers in Obesity and Related Metabolic and Cardiovascular Diseases
Current Pharmaceutical Design Blood Pressure and the Risk of Dementia: A Dose-Response Meta-Analysis of Prospective Studies
Current Neurovascular Research Age-Related Pharmacokinetic and Pharmacodynamic Changes and Related Risk of Adverse Drug Reactions
Current Medicinal Chemistry Vasorelaxant and Antihypertensive Effects of <i>Mentha pulegium</i> L. in Rats: An In vitro and In vivo Approach
Endocrine, Metabolic & Immune Disorders - Drug Targets Inflammation as the Common Biological Link Between Depression and Cardiovascular Diseases: Can Carnosine Exert a Protective Role?
Current Medicinal Chemistry Hyperfibrinogenemia is Significantly Associated with an Increased Risk of In-hospital Mortality in Acute Ischemic Stroke Patients
Current Neurovascular Research Biomarkers of Subclinical Atherosclerosis and Natural Products as Complementary Alternative Medicine
Current Pharmaceutical Design Recommendations for the Treatment of Hypertension in Patients with DM: Critical Evaluation Based on Clinical Trials
Current Clinical Pharmacology